ArticleCancers2022
Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06043661 (An Evaluation of a Circulating Tumor Cell-based Test), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Evaluation of a Circulating Tumor Cell-based Test (TriNetra™-Breast) for Breast Cancer Screening in Women Aged 40 and Above
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine.Molecular biology reports · 2026Review
- Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers.Cancers · 2026Review
- Diagnostic efficacy of circulating tumor cell in clinically significant prostate cancer.Scientific reports · 2026Article
- Breast ultrasound images for segmentation and classification using multi-task U-Net.Scientific reports · 2026Article
- Medicaid Expansion and Overall Mortality Among Women With Breast Cancer.JAMA network open · 2026Article
- Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective.Frontiers in immunology · 2026Review
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- Critical appraisal of the 2 mm threshold in ductal carcinoma in situ: methodological concerns in meta-analysis of margin width and local recurrence risk.Gland surgery · 2025Article
- Liquid biopsy in breast cancer: a practical guide for surgeons.Gland surgery · 2025Review
- Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.International journal of clinical oncology · 2025Review
- Could circulating tumor cells explain why breast conservation improves survival despite higher locoregional recurrence?Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Article
- Axillary management in patients with sentinel lymph node micrometastases following neoadjuvant systemic therapy: a call for de-escalation.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Article
- The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection.Exploration of targeted anti-tumor therapy · 2025Review
- Repeat breast-conserving surgery (BCS) for in breast tumor recurrence after initial BCS for ductal carcinomaGland surgery · 2024Article
- Review
- Reassessing treatment strategies for DCIS: analysis of survival and recurrence patterns.Breast cancer research and treatment · 2024Article
- Article
- Review
- Article
- Status of breast cancer detection in young women and potential of liquid biopsy.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early detection of breast cancer (BrC) is associated with improved survival. We describe a blood-based breast cancer detection test based on functional enrichment of breast-adenocarcinoma-associated circulating tumor cells (BrAD-CTCs) and their identification via multiplexed fluorescence immunocytochemistry (ICC) profiling for GCDFP15, GATA3, EpCAM, PanCK, and CD45 status.
methodsThe ability of the test to differentiate BrC cases (
resultsThe test accurately detects BrAD-CTCs in breast cancers, irrespective of age, ethnicity, disease stage, grade, or hormone receptor status. Analytical validation established the high accuracy and reliability of the test under intended use conditions. The test detects and differentiates BrC cases from healthy women with 100% specificity and 92.07% overall sensitivity in a case-control study. In a prospective clinical study, the test shows 93.1% specificity and 94.64% overall sensitivity in differentiating breast cancer cases (
conclusionThe findings reported in this manuscript support the clinical potential of this test for blood-based BrC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.